| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-10-4179 |
| P698 | PubMed publication ID | 21708957 |
| P50 | author | Isabelle Cremer | Q28317113 |
| Catherine Sautès-Fridman | Q40020459 | ||
| Wolf Hervé Fridman | Q40876588 | ||
| Sophia Platonova | Q118383367 | ||
| Lucile Crozet | Q118383368 | ||
| P2093 | author name string | Marco Alifano | |
| Diane Damotte | |||
| Marie-Caroline Dieu-Nosjean | |||
| Pierre Validire | |||
| Vincent Vieillard | |||
| Julien Cherfils-Vicini | |||
| Jean-François Régnard | |||
| Pascale André | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| lung carcinoma | Q18556110 | ||
| P304 | page(s) | 5412-5422 | |
| P577 | publication date | 2011-06-27 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma | |
| P478 | volume | 71 |
| Q35131244 | A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis |
| Q44717067 | Alterations of oncogenes expression in NK cells in patients with cancer |
| Q46186877 | Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients |
| Q55252861 | Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. |
| Q91971683 | An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More |
| Q60302404 | Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells |
| Q90506533 | B cell and B cell-related pathways for novel cancer treatments |
| Q92299151 | Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells |
| Q34658702 | CD11b(-)CD27(-) NK cells are associated with the progression of lung carcinoma |
| Q89996479 | Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2 |
| Q36130505 | Cellular and molecular immunology of lung cancer: therapeutic implications. |
| Q27329648 | Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids |
| Q27012852 | Characteristics of tertiary lymphoid structures in primary cancers |
| Q35719855 | Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients |
| Q92845938 | Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming |
| Q38855882 | Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma |
| Q38559350 | Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity |
| Q30648415 | Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids |
| Q36821101 | Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. |
| Q38207947 | Effect of tumor cells and tumor microenvironment on NK-cell function. |
| Q38819280 | Emerging insights into natural killer cells in human peripheral tissues. |
| Q90748125 | Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal-Maternal Interface |
| Q92601787 | Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation |
| Q38671184 | Exploiting natural killer group 2D receptors for CAR T-cell therapy. |
| Q88550353 | Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome |
| Q52725437 | Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment. |
| Q28088304 | From mice to humans: developments in cancer immunoediting |
| Q60960579 | Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients |
| Q47680181 | High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer |
| Q35987354 | Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer |
| Q92341987 | Host tissue determinants of tumour immunity |
| Q41474657 | How melanoma cells inactivate NK cells |
| Q38004630 | Human NK cell recognition of target cells in the prism of natural cytotoxicity receptors and their ligands. |
| Q38196803 | Human NK cells: from surface receptors to the therapy of leukemias and solid tumors |
| Q38569646 | Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. |
| Q59136348 | Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration |
| Q42279197 | Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. |
| Q37191088 | IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment |
| Q39259470 | IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients |
| Q61803780 | Immune Cell Composition in Human Non-small Cell Lung Cancer |
| Q56892179 | Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers |
| Q38007549 | Immune alterations and emerging immunotherapeutic approaches in lung cancer |
| Q53743967 | Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies. |
| Q38840291 | Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. |
| Q92768544 | Immunometabolism: A new target for improving cancer immunotherapy |
| Q26750617 | Immunotherapy for lung cancer: advances and prospects |
| Q30422102 | Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma |
| Q92783338 | Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response |
| Q64255314 | Innate Lymphoid Cells in Mucosal Immunity |
| Q40692653 | Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression |
| Q36057423 | Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer |
| Q38181691 | Lung cancer: potential targets for immunotherapy |
| Q36584068 | Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells |
| Q59793946 | Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients |
| Q64066131 | Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy |
| Q39348282 | Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. |
| Q44837814 | Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. |
| Q34541173 | NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome |
| Q90265781 | NK Cell Dysfunction and Checkpoint Immunotherapy |
| Q39431541 | NK Cell Exhaustion. |
| Q90229650 | NK Cell Hyporesponsiveness: More Is Not Always Better |
| Q90226003 | NK Cell Plasticity in Cancer |
| Q91638860 | NK Cells in the Human Lungs |
| Q26746478 | NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? |
| Q102057122 | NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis |
| Q56965731 | NK cells from pleural effusions are potent antitumor effector cells |
| Q36453421 | NK cells in healthy aging and age-associated diseases |
| Q41967990 | NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies |
| Q27014888 | NKG2D ligands as therapeutic targets |
| Q64102223 | NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment |
| Q37616478 | NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients |
| Q37558627 | NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution |
| Q37688634 | NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint |
| Q43185293 | Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. |
| Q26772347 | Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy |
| Q91782587 | Natural Killer Cells in the Lungs |
| Q38872473 | Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies. |
| Q35743162 | Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differentia |
| Q21131216 | Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies |
| Q57395724 | Natural killer cells and other innate lymphoid cells in cancer |
| Q48130583 | Natural killer cells and tumor metastasis |
| Q38352462 | Natural killer cells as helper cells in dendritic cell cancer vaccines |
| Q36486204 | Natural killer cells in non-hematopoietic malignancies |
| Q33869781 | New insights into the role of EMT in tumor immune escape. |
| Q26829161 | New modalities of cancer treatment for NSCLC: focus on immunotherapy |
| Q38953461 | Novel immunotherapy in the treatment of advanced non-small cell lung cancer |
| Q52716894 | Oncogenes in immune cells as potential therapeutic targets. |
| Q28389236 | Orchestration of angiogenesis by immune cells |
| Q38173706 | Organ-specific phenotypic and functional features of NK cells in humans |
| Q41333332 | Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade |
| Q42209070 | Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. |
| Q37323344 | Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15. |
| Q35034899 | Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages |
| Q35677351 | Present and Future of Allogeneic Natural Killer Cell Therapy |
| Q97883497 | Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis |
| Q38394496 | Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma |
| Q37616484 | Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer |
| Q55440274 | Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. |
| Q33798257 | Rad52 deficiency decreases development of lung squamous cell carcinomas by enhancing immuno-surveillance |
| Q26752551 | Regulation of Natural Killer Cell Function by STAT3 |
| Q33714165 | Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade |
| Q43180026 | Reversal of natural killer cell exhaustion by TIM-3 blockade |
| Q48240289 | Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-γ and induces NK cell-dependent lymphoma control without other immunotherapies. |
| Q39210022 | Role of Distinct Natural Killer Cell Subsets in Anticancer Response |
| Q38575116 | Role of NK cells in immunotherapy and virotherapy of solid tumors |
| Q93172097 | Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective |
| Q52608280 | Role of natural killer cells in lung cancer. |
| Q49630355 | Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints |
| Q37659765 | TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. |
| Q38200088 | TLR/NCR/KIR: Which One to Use and When? |
| Q64272018 | TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer |
| Q58621104 | TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer |
| Q90693846 | Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance? |
| Q56889003 | Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells |
| Q37995950 | Targeting natural killer cells and natural killer T cells in cancer |
| Q92615075 | Targeting natural killer cells in solid tumors |
| Q39281940 | Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience. |
| Q35110486 | Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity |
| Q41049892 | The breast tumor microenvironment alters the phenotype and function of natural killer cells |
| Q37413162 | The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. |
| Q29620667 | The immune contexture in human tumours: impact on clinical outcome |
| Q37028764 | The immune microenvironment of human tumors: general significance and clinical impact |
| Q34315871 | The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells |
| Q38264982 | The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome |
| Q36629398 | The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer |
| Q35549712 | The role of natural killer cells in pulmonary immunosurveillance |
| Q26744076 | The role of pembrolizumab in the treatment of advanced non-small cell lung cancer |
| Q38039112 | The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy |
| Q38101567 | The tumor microenvironment: a pitch for multiple players. |
| Q57300016 | Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages |
| Q38089253 | Tissue-specific effector functions of innate lymphoid cells. |
| Q91706130 | Transcriptional Characterization Of The Tumor Immune Microenvironment And Its Prognostic Value For Locally Advanced Lung Adenocarcinoma In A Chinese Population |
| Q55107050 | Tumor immunotherapy: New aspects of natural killer cells. |
| Q42398706 | Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker? |
| Q36038484 | Tumor microenvironment in NSCLC suppresses NK cells function |
| Q92990742 | Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer |
| Q26766468 | Tumour progression and metastasis |
| Q90176787 | Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? |
| Q41807120 | When breast cancer cells start to fend the educational process of NK cells off. |
| Q34364808 | mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. |
Search more.